

Harrow (NASDAQ: HROW) posts positive study results for IHEEZO ophthalmic gel, significantly reducing IVT injection patient discomfort.
You can purchase shares of Harrow (NASDAQ:HROW) through any online brokerage.
Other companies in Harrow’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Harrow has a consensus price target of $60.18.
The stock price for Harrow (NASDAQ: HROW) is $28.59 last updated October 23, 2026 at 6:13 PM EDT.
There are no upcoming dividends for Harrow.
Harrow does not have any upcoming earnings scheduled.
There is no upcoming split for Harrow.
Harrow is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to...